Study of ONTAK (Denileukin Diftitox) in Cutaneous T-Cell Lymphoma (CTCL) Patients
The purpose of this study is to compare the effectiveness of two dose levels of ONTAK (denileukin diftitox) in treating patients who have recurrent or persistent cutaneous T-cell lymphoma.
Lymphoma, T-Cell, Cutaneous|Mycosis Fungoides|Sezary Syndrome
DRUG: ONTAK
Objective Rate of Response (ORR), defined as CR + CCR + PR
Time-to-Treatment Failure|Time-to-Progression|Duration of Response
The purpose of this study is to compare the effectiveness of two dose levels of ONTAK (denileukin diftitox) in treating patients who have recurrent or persistent cutaneous T-cell lymphoma.